Pralatrexate pharmacology and clinical development

Clinical Cancer Research

Volumn 19, Issue 24, 2013, Pages 6657-6661

  Marchi, Enrica ^a   Mangone, Michael ^b   Zullo, Kelly ^a   O'Connor, Owen A ^a  

^a NewYork Presbyterian Hospital   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CYANOCOBALAMIN; CYTARABINE; DIHYDROFOLATE REDUCTASE; FOLIC ACID; FOLYLPOLYGLUTAMATE SYNTHASE; GEMCITABINE; METHOTREXATE; PRALATREXATE; REDUCED FOLATE CARRIER; ROMIDEPSIN;

ANGIOIMMUNOBLASTIC T CELL LYMPHOMA; APOPTOSIS; AREA UNDER THE CURVE; B CELL LYMPHOMA; BLOOD TOXICITY; CANCER INHIBITION; CUTANEOUS T CELL LYMPHOMA; DRUG CYTOTOXICITY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG POTENTIATION; FOLATE METABOLISM; HODGKIN DISEASE; HUMAN; LARGE CELL LYMPHOMA; LYMPHOMA; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYCOSIS FUNGOIDES; NONHODGKIN LYMPHOMA; NONHUMAN; OPTIMAL DRUG DOSE; PERIPHERAL T CELL LYMPHOMA; PRIORITY JOURNAL; REVIEW; STOMATITIS; T CELL LYMPHOMA;

AMINOPTERIN; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; DEOXYCYTIDINE; DEPSIPEPTIDES; DISEASE-FREE SURVIVAL; DRUG APPROVAL; DRUG SYNERGISM; HUMANS; LYMPHOMA, T-CELL; MALE; PYRAZINES; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84890631534     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-2251     Document Type: Review

References (22)

1. Zhao R, Matherly LH, Goldman ID. Membrane transporters and folate homeostasis: intestinal absorption and transport into systemic compartments and tissues. Expert Rev Mol Med 2009;11:e4.
2. Farber S, Cutler EC, Hawkins JW, Harrison JH, Peirce EC II, Lenz GG. The action of pteroylglutamic conjugates on man. Science 1947;106: 619-21.
3. Farber S, Diamond LK. Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid. N Engl J Med 1948;238:787-93.
4. Sirotnak FM, DeGraw JI, Chello PL, Moccio DM, Dorick DM. Biochemical and pharmacologic properties of a new folate analog, 10-deaza-aminopterin, in mice. Cancer Treat Rep 1982;66:351-8. (Pubitemid 12169669)
5. DeGraw JI, Colwell WT, Piper JR, Sirotnak FM. Synthesis and antitu-mor activity of 10-propargyl-10-deazaaminopterin. J Med Chem 1993;36:2228-31.
6. Sweiry JH, Yudilevich DL. Transport of folates at maternal and fetal sides of the placenta: lack of inhibition by methotrexate. Biochim Biophys Acta 1985;821:497-501. (Pubitemid 16172510)
7. Goldman ID, Zhao R. Molecular, biochemical, and cellular pharmacology of pemetrexed. Semin Oncol 2002;29(6 Suppl 18):3-17. (Pubitemid 36176669)
8. Marneros AG, Grossman ME, Silvers DN, Husain S, Nuovo GJ, Mac-Gregor-Cortelli B, et al. Pralatrexate-induced tumor cell apoptosis in the epidermis of a patient with HTLV-1 adult T-cell lymphoma/leukemia causing skin erosions. Blood 2009;113:6338-41.
9. Sirotnak FM, DeGraw JI, Moccio DM, Samuels LL, Goutas LJ. New folate analogs of the 10-deaza-aminopterin series. Basis for structural design and biochemical and pharmacologic properties. Cancer Che-mother Pharmacol 1984;12:18-25.
10. Wang ES, O'Connor O, She Y, Zelenetz AD, Sirotnak FM, Moore MA. Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminop-terin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression. Leuk Lymphoma 2003;44:1027-35. (Pubitemid 36417003)
11. Mangone M, Scotto L, Marchi E, O'Connor OA, Cho HJ. Pralatrexate has potent activity against multiple myeloma in vitro and in vivo, and activity correlates with tumor RFC-1 and DHFR expression [abstract]. In: Proceedings of the 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Antonio, TX. Washington, DC: ASH; 2011. Abstract nr 1831.
12. Toner LE, Vrhovac R, Smith EA, Gardner J, Heaney M, Gonen M, et al. The schedule-dependent effects of the novel antifolate pralatrexate and gemcitabine are superior to methotrexate and cytarabine in models of human non-Hodgkin's lymphoma. Clin Cancer Res 2006; 12(3 Pt 1):924-32. (Pubitemid 43259875)
13. Zinzani PL, Musuraca G, Tani M, Stefoni V, Marchi E, Fina M, et al. Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. J Clin Oncol 2007;25:4293-7. (Pubitemid 47548570)
14. Marchi E, Paoluzzi L, Scotto L, Seshan VE, Zain JM, Zinzani PL, et al. Pralatrexate is synergistic with the proteasome inhibitor bortezomib in in vitro and in vivo models of T-cell lymphoid malignancies. Clin Cancer Res 2010;16:3648-58.
15. Krug LM, Heelan RT, Kris MG, Venkatraman E, Sirotnak FM. Phase II trial of pralatrexate (10-propargyl-10-deazaaminopterin, PDX) in patients with unresectable malignant pleural mesothelioma. J Thorac Oncol 2007;2:317-20. (Pubitemid 47181715)
16. Mould DR, Sweeney K, Duffull SB, Neylon E, Hamlin P, Horwitz S, et al. A population pharmacokinetic and pharmacodynamic evaluation of pralatrexate in patients with relapsed or refractory non-Hodgkin's or Hodgkin's lymphoma. Clin Pharmacol Ther 2009;86:190-6.
17. O'Connor OA, Horwitz S, Hamlin P, Portlock C, Moskowitz CH, Sarasohn D, et al. Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies. J Clin Oncol 2009; 27:4357-64.
18. O'Connor OA, Hamlin PA, Portlock C, Moskowitz CH, Noy A, Straus DJ, et al. Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma. Br J Haematol 2007;139:425-8. (Pubitemid 47512170)
19. O'Connor OA, Pro B, Pinter-Brown L, Bartlett N, Popplewell L, Coiffier B, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol 2011;29:1182-9.
20. Foss F, Horwitz SM, Coiffier B, Bartlett N, Popplewell L, Pro B, et al. Pralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides: a subgroup efficacy analysis from the PROPEL study. Clin Lymphoma Myeloma Leuk 2012;12:238-43.
21. Horwitz SM, Kim Y, Foss F, Zain JM, Myskowski P, Lechowicz MJ, et al. Identification of an active, well tolerated dose of pralatrexate in patients with relasped or refractory cutaneous T-cell lymphoma (CTCL). Blood 2012;119:4115-22.
22. Jain S, Scotto L, Marchi E, Kalac M, Amengual J, Buitrago JB, et al. Validation of a novel bioluminescent mouse model of sezary syndrome for preclinical drug screening [abstract]. In: Proceedings of the 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Antonio, TX. Washington, DC: ASH; 2011. Abstract nr 2725.